Why is some performance enhancement OK but not others?

80 Comments

Dan LeBatard offers the most intelligent and mature take on PEDs in sports I’ve seen in ages. He asks us to take a step back and ask ourselves why it is we are so hung up on a certain, narrow kind of performance enhancement in sports when we never question it — indeed, we openly praise it — when athletes do insane things to their bodies, all in the name of staying on the field? Often things that could cause massive harm.

Stuff like Ronnie Lott cutting his finger off. Lomas Brown playing with a catheter. Players having ligaments taken from cadavers and inserted into their own bodies. Drug therapies and medical procedures that are wholly unnecessary for a normal quality of life but are accepted in the name of athletic performance. We are totally fine with these. We are not totally fine with others:

We are OK with Kirk Gibson hitting one of the most famous home runs ever on one steroid (cortisone), but we slam the Hall of Fame door on the face of everybody else who might have used the anabolic kind. Granted, cortisone is not a banned performance enhancer, but it certainly enhanced Gibson’s performance, which wouldn’t have been possible without it. Lost in the shouting of “Cheater!” and “Fraud!” from a pill-popping America is how often athletes have to go through the pharmacy for the healing properties of hormones — not just to hit home runs but because what they do for a daily living really hurts.

It is not enough to draw some line and say “well, [drug/procedure X] is banned and [drug/procedure Y] is not banned.” It makes people who like to pour crap on banned PED users feel better, but it’s a most pedantic distinction. Why are some procedures and drugs banned and others not? Why do we allow some sorts of performance enhancement or enabling but not others? If it’s OK for Kirk Gibson to take a drug that allowed him to take the field when he otherwise could not have, why do we not allow other players to take other drugs that allow them to take the field when they otherwise can’t?

More broadly, as fans and observers, why do we seem to care so much and get so annoyed at certain sorts of seemingly unnatural acts undertaken by athletes but don’t care a bit — or, alternatively, fully expect — so many others?

The Blue Jays are allergic to .500

Tom Pennington/Getty Images
3 Comments

The Blue Jays dropped Thursday afternoon’s game to the Rangers 11-4, splitting the four-game home series. And, impressively, the Blue Jays failed for the ninth time to get back to .500. The club is now 35-37.

Here’s a look at all the times the Blue Jays could’ve evened out their won-lost record and what happened:

  • April 5 (0-1): Lost 3-1 to the Orioles
  • April 7 (1-2): Lost 10-8 to the Rays
  • June 1 (26-27): Lost 12-2 to the Yankees
  • June 3 (27-28): Lost 7-0 to the Yankees
  • June 5 (28-29): Lost 5-3 to the Athletics
  • June 13 (31-32): Lost 8-1 to the Rays
  • June 16 (32-33): Lost 11-4 to the White Sox
  • June 20 (34-35): Lost 6-1 to the Rangers
  • June 22 (35-36): Lost 11-4 to the Rangers

The Blue Jays are now a half-game behind the Orioles for fifth place in the AL East, but they’re only 5.5 games behind the first-place Yankees. Interestingly, if the Blue Jays played in the NL East and had the same record, they would be in second place. But even the Phillies — baseball’s worst team — have been at .500 or better for a few days: after winning Opening Day and after game Nos. 6, 18, 19, 20, 21, and 22.

Report: Marlins expected to trade Adeiny Hechavarria

Joe Robbins/Getty Images
2 Comments

Jeff Passan of Yahoo Sports reports that the Marlins are expected to trade shortstop Adeiny Hechavarria in the next few days.

Hechavarria, 28, is currently on a rehab assignment for a strained left oblique. It’s the second time this season he’s hit the sidelines with an oblique injury. Hechavarria is also hitting a disappointing .277/.288/.385 over 67 plate appearances, which is marginally better than his career averages.

While the Marlins are shopping Hechavarria at depressed value, there are two factors that give him value: he still plays good defense, and he’s under team control through the 2018 season. Passan does estimate that Hechavarria will see a pay raise from $4.3 million this season to $6-7 million next season in his third and final year of arbitration eligibility.

Passan adds that while the Marlins aren’t yet willing to shop outfielders Christian Yelich and Marcell Ozuna, relievers A.J. Ramos, David Phelps, and Kyle Barraclough are being made available.